CooperSurgical terminates InnerDyne agreement:
This article was originally published in Clinica
Executive Summary
CooperSurgical has terminated an agreement to fund the development and clinical trials of InnerDyne's thermal endometrial ablation technology for gynaecological applications. The termination was due to delays in product development which prevented CooperSurgical from fully evaluating the system's clinical safety and efficacy, says the company. CooperSurgical also claims competing endometrial ablation technologies are more likely to gain market approval before InnerDyne's products. Nicholas Pichotta, CooperSurgical's president, says his company is currently pursuing other opportunities to acquire or licence additional products within the surgical gynaecology strategy.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.